PMID- 10383135
OWN - NLM
STAT- MEDLINE
DCOM- 19990719
LR  - 20031114
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 59
IP  - 12
DP  - 1999 Jun 15
TI  - Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor 
      cells generates systemic antitumor immunity.
PG  - 2802-5
AB  - Dendritic cells (DCs) are potent antigen-presenting cells that are capable of 
      priming systemic antitumor immune responses in animal tumor models. However, many 
      of the model tumor systems tested need definition of the specific tumor antigens 
      involved. To use DCs in situations that are more relevant to the majority of 
      human cancers, where the antigens are unknown, we have tested the adoptive 
      transfer of immature DCs in mouse colorectal and melanoma models of varying 
      immunogenicity but with undefined antigens. When DCs admixed with a syngeneic 
      primary tumor inoculum were seeded s.c., the growth of the primary tumor was 
      unchanged; however, if the primary tumor was then surgically excised and the 
      animal was rechallenged with the same tumor, significant protection (75%) was 
      generated when DCs were present in the original primary inoculum of a moderately 
      immunogenic colorectal model (CMT93tk). This effect was not observed when a 
      nonimmunogenic melanoma (B16) was tested in an identical protocol. Next, DCs were 
      injected directly into 6-9-mm established tumors; again, protection (55%) was 
      achieved against a secondary tumor challenge following excision of the primary, 
      but only in the CMT93tk model of moderate immunogenicity. To increase the 
      clinical relevance of this approach still further, we tested irradiated 
      allogeneic K1735 melanoma cells mixed with syngeneic DCs as a vaccine against 
      subsequent challenge with the poorly immunogenic syngeneic melanoma B16. The 
      allogeneic vaccine alone was ineffective, but when admixed with DCs, a 
      significant number of animals rejected a subsequent B16 challenge, suggesting 
      that DCs are able to prime an immune response against melanoma antigens shared 
      between K1735 and B16. The generation of systemic antitumor immunity by adoptive 
      transfer of DCs has significant clinical potential because it is technically 
      straightforward and does not require the definition of specific tumor antigens.
FAU - Melcher, A
AU  - Melcher A
AD  - Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA.
FAU - Todryk, S
AU  - Todryk S
FAU - Bateman, A
AU  - Bateman A
FAU - Chong, H
AU  - Chong H
FAU - Lemoine, N R
AU  - Lemoine NR
FAU - Vile, R G
AU  - Vile RG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Cancer Vaccines)
RN  - 0 (Isoantigens)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/immunology
MH  - Cells, Cultured
MH  - Dendritic Cells/*transplantation
MH  - Disease Models, Animal
MH  - Immunity
MH  - Immunotherapy
MH  - *Immunotherapy, Adoptive
MH  - Isoantigens
MH  - Melanoma, Experimental/immunology/*therapy
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasm Transplantation
MH  - Transplantation, Autologous
EDAT- 1999/06/26 00:00
MHDA- 1999/06/26 00:01
CRDT- 1999/06/26 00:00
PHST- 1999/06/26 00:00 [pubmed]
PHST- 1999/06/26 00:01 [medline]
PHST- 1999/06/26 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1999 Jun 15;59(12):2802-5.